These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35049017)

  • 1. Prostacyclins and pulmonary arterial hypertension in children.
    Wu Y; Liu HM; Gu L; Li QW; Zhu L
    Eur Rev Med Pharmacol Sci; 2022 Jan; 26(1):37-45. PubMed ID: 35049017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled Therapies for Pulmonary Hypertension.
    Hill NS; Preston IR; Roberts KE
    Respir Care; 2015 Jun; 60(6):794-802; discussion 802-5. PubMed ID: 26070575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of prostacyclin and its analogs in the management of pulmonary arterial hypertension.
    Dandel M; Hetzer R
    Curr Vasc Pharmacol; 2003 Jun; 1(2):171-81. PubMed ID: 15320842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies.
    Waxman AB; Zamanian RT
    Am J Cardiol; 2013 Mar; 111(5 Suppl):1A-16A; quiz 17A-19A. PubMed ID: 23414683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostanoid therapy for pulmonary arterial hypertension.
    Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostacyclin therapy for pulmonary arterial hypertension: new directions.
    Gomberg-Maitland M; Preston IR
    Semin Respir Crit Care Med; 2005 Aug; 26(4):394-401. PubMed ID: 16121316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolution of prostacyclins in pulmonary arterial hypertension: from classical treatment to modern management.
    Burger CD; D'Albini L; Raspa S; Pruett JA
    Am J Manag Care; 2016 Jan; 22(1 Suppl):S3-15. PubMed ID: 26885569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled treprostinil and pulmonary arterial hypertension.
    Nadler ST; Edelman JD
    Vasc Health Risk Manag; 2010 Dec; 6():1115-24. PubMed ID: 21191432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostacyclin in the intensive care setting.
    Ivy DD
    Pediatr Crit Care Med; 2010 Mar; 11(2 Suppl):S41-5. PubMed ID: 20216163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
    Gessler T; Seeger W; Schmehl T
    Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhalation of repurposed drugs to treat pulmonary hypertension.
    Gessler T
    Adv Drug Deliv Rev; 2018 Aug; 133():34-44. PubMed ID: 29886070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of inhaled iloprost for the control of pulmonary artery hypertension in children.
    Tissot C; Beghetti M
    Vasc Health Risk Manag; 2009; 5(1):325-31. PubMed ID: 19436672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
    Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
    Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
    Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
    Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of iloprost and bosentan in pulmonary arterial hypertension.
    Saleh JA
    Niger J Med; 2008; 17(1):13-9. PubMed ID: 18390125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
    Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
    Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostanoid therapy for pulmonary arterial hypertension.
    Strauss WL; Edelman JD
    Clin Chest Med; 2007 Mar; 28(1):127-42; ix. PubMed ID: 17338932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.